• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Pepticom Secures $6.6M to Advance AI-Powered Peptide Drug Discovery

by Fred Pennic 01/07/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Pepticom Secures $6.6M to Advance AI-Powered Peptide Drug Discovery

What You Should Know: 

– Pepticom, an innovator in AI-driven peptide-based therapeutics secures $6.6M in a Series A1 funding round led by Japan Israel High Tech Ventures 2 LP, with strong support from existing investors. 

– The new funding will accelerate the development of Pepticom’s oral IL-17 inhibitor program, focusing on creating improved treatments for autoimmune diseases like psoriasis and psoriatic arthritis.

Revolutionizing Autoimmune Disease Treatment

Pepticom is developing two families of fully synthetic, small cyclic peptidomimetic inhibitors that target both IL-17A and IL-17F isoforms, key drivers of inflammation in autoimmune diseases. These innovative compounds, composed of non-natural amino acids, have demonstrated remarkable progress, achieving key milestones in record time and cost. Notably, they exhibit increased stability and extended half-life in both in vitro and in vivo studies.

AI-Powered Peptide Drug Discovery

Pepticom’s proprietary platform combines cutting-edge AI and machine learning with advanced biochemistry to design peptides with exceptional specificity, stability, and therapeutic potential. By leveraging a vast library of over 600 natural and non-natural amino acid building blocks, Pepticom can explore an immense chemical space of over 10⁸⁰ potential peptide structures.

This unique approach allows for the de novo design and discovery of entirely new peptidomimetic targets, offering significant advantages over traditional small molecule and biologic therapies. Pepticom’s AI-driven platform accelerates the drug discovery process, bringing innovative peptide therapies to patients faster and at a lower cost.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Drug Discovery

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

The AI Paradox in Healthcare: Notable CEO Shares Why Moving Too Slowly is a Greater Risk

Most-Read

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Patient Square Capital Acquires Premier in $2.6B Deal

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |